|
1
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Swain SM, Shastry M and Hamilton E:
Targeting HER2-positive breast cancer: Advances and future
directions. Nat Rev Drug Discov. 22:101–126. 2023. View Article : Google Scholar
|
|
3
|
Swain SM, Baselga J, Kim SB, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Heeson S, et al: Pertuzumab, trastuzumab, and docetaxel in
HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu L, Xie Y, Gou Q, Cai R, Bao R, Huang Y
and Tang R: HER2-targeted therapies for HER2-positive early-stage
breast cancer: present and future. Front Pharmacol. 15:14464142024.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhu K, Yang X, Tai H, Zhong X, Luo T and
Zheng H: HER2-targeted therapies in cancer: A systematic review.
Biomark Res. 12:162024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sánchez-Lorenzo L, Bachiller A, Gea C and
Espinós J: Current management and future perspectives in metastatic
HER2-positive breast cancer. Semin Oncol Nurs. 40:1515542024.
View Article : Google Scholar
|
|
7
|
Arteaga CL and Engelman JA: ERBB
receptors: From oncogene discovery to basic science to
mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chu X, Tian W, Ning J, Xiao G, Zhou Y,
Wang Z, Zhai Z, Tanzhu G, Yang J and Zhou R: Cancer stem cells:
Advances in knowledge and implications for cancer therapy. Signal
Transduct Target Ther. 9:1702024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pattabiraman DR and Weinberg RA: Tackling
the cancer stem cells-what challenges do they pose? Nat Rev Drug
Discov. 13:497–512. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ginestier C, Hur MH, Charafe-Jauffret E,
Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG,
Liu S, et al: ALDH1 is a marker of normal and malignant human
mammary stem cells and a predictor of poor clinical outcome. Cell
Stem Cell. 1:555–567. 2007. View Article : Google Scholar
|
|
11
|
Shah D and Osipo C: Cancer stem cells and
HER2 positive breast cancer: The story so far. Genes Dis.
3:114–123. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duru N, Fan M, Candas D, Menaa C, Liu HC,
Nantajit D, Wen Y, Xiao K, Eldridge A, Chromy BA, et al:
HER2-associated radioresistance of breast cancer stem cells
isolated from HER2-negative breast cancer cells. Clin Cancer Res.
18:6634–6647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Korkaya H and Wicha MS: HER2 and breast
cancer stem cells: More than meets the eye. Cancer Res.
73:3489–3493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xia Y, Sun M, Huang H and Jin WL: Drug
repurposing for cancer therapy. Signal Transduct Target Ther.
9:922024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim JY, Cho Y, Oh E, Lee N, An H, Sung D,
Cho TM and Seo JH: Disulfiram targets cancer stem-like properties
and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Cancer Lett. 379:39–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen D, Cui QC, Yang H and Dou QP:
Disulfiram, a clinically used anti-alcoholism drug and
copper-binding agent, induces apoptotic cell death in breast cancer
cultures and xenografts via inhibition of the proteasome activity.
Cancer Res. 66:10425–10433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Serageldin MA, El-Bassiouny NA, El-Kerm Y,
Aly RG, Helmy MW, El-Mas MM and Kassem AB: A randomized controlled
study of neoadjuvant metformin with chemotherapy in nondiabetic
breast cancer women: The METNEO study. Br J Clin Pharmacol.
90:3160–3175. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goodwin PJ, Chen BE, Gelmon KA, Whelan TJ,
Ennis M, Lemieux J, Ligibel JA, Hershman DL, Mayer IA, Hobday TJ,
et al: Effect of metformin vs placebo on invasive disease-free
survival in patients with breast cancer: The MA.32 randomized
clinical trial. JAMA. 327:1963–1973. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roberts DJ: A preclinical overview of
ebastine. Studies on the pharmacological properties of a novel
histamine H1 receptor antagonist. Drugs. 52(Suppl 1): S8–S14. 1996.
View Article : Google Scholar
|
|
20
|
Noveck RJ, Preston RA and Swan SK:
Pharmacokinetics and safety of ebastine in healthy subjects and
patients with renal impairment. Clin Pharmacokinet. 46:525–534.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Q, Liu KY, Liu Q, Wang G, Jiang W, Meng
Q, Yi Y, Yang Y, Wang R, Zhu S, et al: Antihistamine drug ebastine
inhibits cancer growth by targeting polycomb group protein EZH2.
Mol Cancer Ther. 19:2023–2033. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seo J, Park M, Ko D, Kim S, Park JM, Park
S, Nam KD, Farrand L, Yang J, Seok C, et al: Ebastine impairs
metastatic spread in triple-negative breast cancer by targeting
focal adhesion kinase. Cell Mol Life Sci. 80:1322023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pan Z, Li SJ, Guo H, Li ZH, Fei X, Chang
SM, Yang QC and Cheng DD: Ebastine exerts antitumor activity and
induces autophagy by activating AMPK/ULK1 signaling in an
IPMK-dependent manner in osteosarcoma. Int J Biol Sci. 19:537–551.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park SJ, Yoon BH, Kim SK and Kim SY:
GENT2: An updated gene expression database for normal and tumor
tissues. BMC Med Genomics. 12(Suppl 5): S1012019. View Article : Google Scholar
|
|
26
|
Wiseman LR and Faulds D: Ebastine. a
review of its pharmacological properties and clinical efficacy in
the treatment of allergic disorders. Drugs. 51:260–277. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanner M, Kapanen AI, Junttila T, Raheem
O, Grenman S, Elo J, Elenius K and Isola J: Characterization of a
novel cell line established from a patient with Herceptin-resistant
breast cancer. Mol Cancer Ther. 3:1585–1592. 2004. View Article : Google Scholar
|
|
28
|
Vranic S, Gatalica Z and Wang ZY: Update
on the molecular profile of the MDA-MB-453 cell line as a model for
apocrine breast carcinoma studies. Oncol Lett. 2:1131–1137. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park M, Jung E, Park JM, Park S, Ko D, Seo
J, Kim S, Nam KD, Kang YK, Farrand L, et al: The HSP90 inhibitor
HVH-2930 exhibits potent efficacy against trastuzumab-resistant
HER2-positive breast cancer. Theranostics. 14:2442–2463. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang ZH, Zheng ZQ, Jia SC, Liu SN, Xiao
XF, Chen GY, Liang WQ and Lu XF: Trastuzumab resistance in
HER2-positive breast cancer: Mechanisms, emerging biomarkers and
targeting agents. Front Oncol. 12:10064292022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chandarlapaty S, Scaltriti M, Angelini P,
Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J
and Rosen N: Inhibitors of HSP90 block p95-HER2 signaling in
trastuzumab-resistant tumors and suppress their growth. Oncogene.
29:325–334. 2010. View Article : Google Scholar
|
|
32
|
Yang M, Li Y, Kong L, Huang S, He L, Liu
P, Mo S, Lu X, Lin X, Xiao Y, et al: Inhibition of DPAGT1
suppresses HER2 shedding and trastuzumab resistance in human breast
cancer. J Clin Invest. 133:e1644282023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Baselga J and Swain SM: Novel anticancer
targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer.
9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Korkaya H, Paulson A, Iovino F and Wicha
MS: HER2 regulates the mammary stem/progenitor cell population
driving tumorigenesis and invasion. Oncogene. 27:6120–6130. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Oh E, Kim YJ, An H, Sung D, Cho TM,
Farrand L, Jang S, Seo JH and Kim JY: Flubendazole elicits
anti-metastatic effects in triple-negative breast cancer via STAT3
inhibition. Int J Cancer. 143:1978–1993. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Idowu MO, Kmieciak M, Dumur C, Burton RS,
Grimes MM, Powers CN and Manjili MH: CD44(+)/CD24(-/low) cancer
stem/progenitor cells are more abundant in triple-negative invasive
breast carcinoma phenotype and are associated with poor outcome.
Hum Pathol. 43:364–373. 2012. View Article : Google Scholar
|
|
38
|
Boulbes DR, Chauhan GB, Jin Q,
Bartholomeusz C and Esteva FJ: CD44 expression contributes to
trastuzumab resistance in HER2-positive breast cancer cells. Breast
Cancer Res Treat. 151:501–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pushpakom S, Iorio F, Eyers PA, Escott KJ,
Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et
al: Drug repurposing: Progress, challenges and recommendations. Nat
Rev Drug Discov. 18:41–58. 2019. View Article : Google Scholar
|
|
40
|
Armando RG, Mengual Gómez DL and Gomez DE:
New drugs are not enough-drug repositioning in oncology: An update.
Int J Oncol. 56:651–684. 2020.PubMed/NCBI
|
|
41
|
Simons FER and Simons KJ: H1
antihistamines: Current status and future directions. World Allergy
Organ J. 1:145–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hurst M and Spencer CM: Ebastine: An
update of its use in allergic disorders. Drugs. 59:981–1006. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schlam I, Tarantino P and Tolaney SM:
Overcoming resistance to HER2-directed therapies in breast cancer.
Cancers (Basel). 14:39962022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pourjamal N, Yazdi N, Halme A, Joncour VL,
Laakkonen P, Saharinen P, Joensuu H and Barok M: Comparison of
trastuzumab emtansine, trastuzumab deruxtecan, and disitamab
vedotin in a multiresistant HER2-positive breast cancer lung
metastasis model. Clin Exp Metastasis. 41:91–102. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pályi-Krekk Z, Barok M, Isola J, Tammi M,
Szöllosi J and Nagy P: Hyaluronan-induced masking of ErbB2 and
CD44-enhanced trastuzumab internalisation in trastuzumab resistant
breast cancer. Eur J Cancer. 43:2423–2433. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim YJ, Sung D, Oh E, Cho Y, Cho TM,
Farrand L, Seo JH and Kim JY: Flubendazole overcomes trastuzumab
resistance by targeting cancer stem-like properties and HER2
signaling in HER2-positive breast cancer. Cancer Lett. 412:118–130.
2018. View Article : Google Scholar
|
|
48
|
Chen C, Zhao S, Karnad A and Freeman JW:
The biology and role of CD44 in cancer progression: Therapeutic
implications. J Hematol Oncol. 11:642018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ouhtit A, Rizeq B, Saleh HA, Rahman MM and
Zayed H: Novel CD44-downstream signaling pathways mediating breast
tumor invasion. Int J Biol Sci. 14:1782–1790. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Berr AL, Wiese K, Dos Santos G, Koch CM,
Anekalla KR, Kidd M, Davis JM, Cheng Y, Hu YS and Ridge KM:
Vimentin is required for tumor progression and metastasis in a
mouse model of non-small cell lung cancer. Oncogene. 42:2074–2087.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Grasset EM, Dunworth M, Sharma G, Loth M,
Tandurella J, Cimino-Mathews A, Gentz M, Bracht S, Haynes M, Fertig
EJ and Ewald AJ: Triple-negative breast cancer metastasis involves
complex epithelial-mesenchymal transition dynamics and requires
vimentin. Sci Transl Med. 14:eabn75712022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Winter M, Meignan S, Völkel P, Angrand PO,
Chopin V, Bidan N, Toillon RA, Adriaenssens E, Lagadec C and Le
Bourhis X: Vimentin promotes the aggressiveness of triple negative
breast cancer cells surviving chemotherapeutic treatment. Cells.
10:15042021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li F, Zhang L, Feng F, Zheng K, Li Y, Wang
T and Ren G: Livin participates in resistance to trastuzumab
therapy for breast cancer through ERK1/2 and AKT pathways and
promotes EMT-like phenotype. RSC Adv. 8:28588–28601. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu
Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, et al:
Breast cancer stem cells transition between epithelial and
mesenchymal states reflective of their normal counterparts. Stem
Cell Reports. 2:78–91. 2013. View Article : Google Scholar
|
|
55
|
Usman S, Waseem NH, Nguyen TKN, Mohsin S,
Jamal A, Teh MT and Waseem A: Vimentin Is at the heart of
epithelial mesenchymal transition (EMT) mediated metastasis.
Cancers (Basel). 13:49852021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
van Beijnum JR, Huijbers EJM, van Loon K,
Blanas A, Akbari P, Roos A, Wong TJ, Denisov SS, Hackeng TM,
Jimenez CR, et al: Extracellular vimentin mimics VEGF and is a
target for anti-angiogenic immunotherapy. Nat Commun. 13:28422022.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Dave JM and Bayless KJ: Vimentin as an
integral regulator of cell adhesion and endothelial sprouting.
Microcirculation. 21:333–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Shah D, Wyatt D, Baker AT, Simms P,
Peiffer DS, Fernandez M, Rakha E, Green A, Filipovic A, Miele L and
Osipo C: Inhibition of HER2 increases JAGGED1-dependent breast
cancer stem cells: Role for membrane JAGGED1. Clin Cancer Res.
24:4566–4578. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hangauer MJ, Viswanathan VS, Ryan MJ, Bole
D, Eaton JK, Matov A, Galeas J, Dhruv HD, Berens ME, Schreiber SL,
et al: Drug-tolerant persister cancer cells are vulnerable to GPX4
inhibition. Nature. 551:247–250. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Huang WC, Hung CM, Wei CT, Chen TM, Chien
PH, Pan HL, Lin YM and Chen YJ: Interleukin-6 expression
contributes to lapatinib resistance through maintenance of stemness
property in HER2-positive breast cancer cells. Oncotarget.
7:62352–62363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim JH, Park S, Jung E, Shin J, Kim YJ,
Kim JY, Sessler JL, Seo JH and Kim JS: A dual-action
niclosamide-based prodrug that targets cancer stem cells and
inhibits TNBC metastasis. Proc Natl Acad Sci USA.
120:e23040811202023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ajmeera D and Ajumeera R: Drug
repurposing: A novel strategy to target cancer stem cells and
therapeutic resistance. Genes Dis. 11:148–175. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kim JY, Lee N, Kim YJ, Cho Y, An H, Oh E,
Cho TM, Sung D and Seo JH: Disulfiram induces anoikis and
suppresses lung colonization in triple-negative breast cancer via
calpain activation. Cancer Lett. 386:151–160. 2017. View Article : Google Scholar
|
|
64
|
Kannappan V, Ali M, Small B, Rajendran G,
Elzhenni S, Taj H, Wang W and Dou QP: Recent advances in
repurposing disulfiram and disulfiram derivatives as
copper-dependent anticancer agents. Front Mol Biosci. 8:7413162021.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Cvek B: The promiscuity of disulfiram in
medicinal research. ACS Med Chem Lett. 14:1610–1614. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Vincent J, Liminana R, Meredith PA and
Reid JL: The pharmacokinetics, antihistamine and
concentration-effect relationship of ebastine in healthy subjects.
Br J Clin Pharmacol. 26:497–502. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Saini N and Yang X: Metformin as an
anti-cancer agent: Actions and mechanisms targeting cancer stem
cells. Acta Biochim Biophys Sin (Shanghai). 50:133–143. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Vazquez-Martin A, Oliveras-Ferraros C and
Menendez JA: The antidiabetic drug metformin suppresses HER2
(erbB-2) oncoprotein overexpression via inhibition of the mTOR
effector p70S6K1 in human breast carcinoma cells. Cell Cycle.
8:88–96. 2009. View Article : Google Scholar
|
|
70
|
Tan M, Ye W, Liu Y, Chen X, Huttad L, Chua
MS and So S: Niclosamide prodrug enhances oral bioavailability and
efficacy against hepatocellular carcinoma by targeting vasorin-TGFβ
signalling. Br J Pharmacol. 182:5517–5535. 2025. View Article : Google Scholar : PubMed/NCBI
|
